pembrolizumab
Merck
['hncsm', 'head and neck', 'pembro']
pembrolizumab plus chemoradiation did not meet statistically significant improvement in event-free survival for patients with locally advanced head and neck squamous cell carcinoma. #hncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.